Your search returned 5 results.

Results
	1.	Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors: Swain, Sandra M PMID: 22276821 Year: 2012 Citation: New England Journal of Medicine. 366(4):310-20, 2012 Jan 26. Institution: Washington Cancer Institute Medline publication type: Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Form of publication: Journal Article All authors: Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA DOI: http://dx.doi.org/10.1056/NEJMoa1111097 Add to cart (remove)
	2.	Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. MedStar authors: Swain, Sandra M PMID: 23940225 Year: 2013 Citation: Journal of Clinical Oncology. 31(26):3197-204, 2013 Sep 10. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Form of publication: Journal Article All authors: Atkins JN, Azar CA, Biggs DD, Brufsky AM, Costantino JP, Donnellan PP, Fehrenbacher L, Geyer CE Jr, Levine EA, Mamounas EP, Northfelt DW, Paik S, Polikoff JA, Provencher L, Rastogi P, Robidoux A, Swain SM, Tang G, Wolmark N, Zapas JL DOI: http://dx.doi.org/10.1200/JCO.2012.48.1275 Add to cart (remove)
	3.	Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. MedStar authors: Swain, Sandra M PMID: 26272770 Year: 2015 Citation: Lancet Oncology. 16(9):1037-48, 2015 Sep. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Adams PT, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Liu Q, Mamounas EP, Margolese RG, Mehta RS, Paik S, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA DOI: http://dx.doi.org/10.1016/S1470-2045(15)00041-8 Add to cart (remove)
	4.	Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). MedStar authors: Priebat, Dennis A PMID: 23335221 Citation: Cancer. 119(8):1555-61, 2013 Apr 15. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase II Journal Article Multicenter Study Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Araujo DM, Baker LH, George S, Hensley ML, Maki RG, Priebat DA, Soslow RA, Sutton G, Wathen JK DOI: http://dx.doi.org/10.1002/cncr.27942 Add to cart (remove)
	5.	IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. MedStar authors: Swain, Sandra M MedStar Health PMID: 38755096 Year: 2024 Citation: Annals of Oncology. 35(7):630-642, 2024 Jul. Department: Associate Dean for Research Development Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Form of publication: Journal Article All authors: Dent R, Andre F, Goncalves A, Martin M, Schmid P, Schutz F, Kummel S, Swain SM, Bilici A, Loirat D, Villalobos Valencia R, Im SA, Park YH, De Laurentis M, Colleoni M, Guarneri V, Bianchini G, Li H, Kirchmayer Machackova Z, Mouta J, Deurloo R, Gan X, Fan M, Mani A, Swat A, Cortes J DOI: https://dx.doi.org/10.1016/j.annonc.2024.04.001 Add to cart (remove)

Powered by Koha